Indivior: Is Vivitrol A Threat To Suboxone?
A study sponsored by the National Institute on Drug Abuse compared opioid addition treatments Vivitrol from Alkermes (ALKS), and Indivior's (OTCPK:INVVY) (OTCPK:IZQVF) Suboxone. The...
LeBron’s Dagger Over Porzingis Seals The Deal For Cavs
The Knicks put up a valiant effort through three quarters of Monday night's game against the Cleveland Cavaliers at Madison Square Garden. They dominated...
Rising Tides Lift Weatherford
Weatherford reported Q3 earnings last week. The company delivered revenue of $1.46 billion and eps of -$0.22. The company missed on revenue by $20...
Allergan’s Q3 Proves Growth Is Dead
Allergan (AGN) reported more solid results in Q3, at least on the surface. The company delivered revenue of $4.0 billion and eps of $4.15....
Teva Punished After Weak Outlook
Teva (TEVA) reported Q3 revenue of $5.61 billion and eps of $1.00. The company missed on revenue by $10 million and missed on eps...
Valeant: Uceris Patent Loss Deepens Salix’s Impairment
A Delaware court ruled in favor of Teva (TEVA) in its challenge of patents covering Valeant's Uceris (budesonide ER) tablets:
Teva Pharmaceutical Industries Ltd. (TEVJF),...
Gilead Is Persona Non Grata
lead (GILD) is down over 3% since earnings were released. Heading into earnings I warned that revenue could fall sequentially by 11%. I also...
Allergan: RegenerX’s Stellar Phase 3 Ushers In Another Dry Eye Competitor
The results of RegenerX's phase clinical trials pursuant to dry are in and the company passed with flying colors. Its ARISE-2 trial investigated RGN-259's...
Valeant Settles $13 Million Depomed Dispute. Is $17 Billion Impaired Goodwill Next?
Valeant continues to dominate the news cycle. Its price-gouging put it in the same company as Retrophin which was formerly run by "Pharma Bro"...
Allergan: Is Linzess ‘Restasis 2.0’?
Friday Allergan (AGN) Forest Laboratories ( and Ironwood Pharmaceuticals (IRWD) accused Teva (TEV) of infringing upon a patent for Linzess, which treats irritable bowel...
